Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Radioligand Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HRS-4357-101 | P2 |
Not yet recruiting |
Prostate Cancer |
2024-09-30 |
34% |
2023-08-24 |
Recent News Events
Date |
Type |
Title |
|---|